TransMedics Q3 revenue $25.7M (+378% YoY); 2022 guidance raised to $80-85M

TransMedics Group, Inc.

2022-Q3 EPS reported -$1.03 revenue$62,084,000

Net revenue $25.7M including $1.4M favorable adjustment; ex-adjustment $24.3M (+349% YoY).
Full-year 2022 revenue guidance raised to $80-85M (ex-adjustment) vs prior $67-75M.
Net loss narrowed to $7.4M from $13.0M in Q3 2021; cash and equivalents $204.5M.
National OCS Program (NOP) drove ~90% of US revenue; public offering netted ~$140M.
Gross margin 71% vs 70% a year ago; operating expenses $23.7M, up from $15.5M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TransMedics Group, Inc. reported full year 2022 results: revenue $80 million to $85 million. Guidance raised.

Period: full year 2022
Revenue: $80 million to $85 million
Guidance: raised
Result: guidance update

Exact text from the filing

TransMedics is updating full year 2022 revenue to be in the range of $80 million to $85 million, excluding the $1.4 million favorable change in estimate for contra revenue, which represents 164% to 181% growth compared to the company’s prior year revenue.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TransMedics Group, Inc. reported the quarter ended September 30, 2022 results: revenue $25.7 million, net income $7.4 million.

Period: the quarter ended September 30, 2022
Revenue: $25.7 million
Net income: $7.4 million
Result: reported results

Exact text from the filing

Net revenue for the third quarter of 2022 was $25.7 million, a 378% increase compared to $5.4 million in the third quarter of 2021.

View on SEC.gov

Browse all earnings releases →

TransMedics Group, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-036614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.